Dupilumab Linked to Increased Risk of Cutaneous T Cell Lymphoma in Atopic Dermatitis Patients: Study
Researchers have found that the use of dupilumab, a human monoclonal antibody targeting the IL-4 alpha receptor, is associated with an increased risk of cutaneous T cell lymphoma (CTCL) in patients with moderate to severe atopic dermatitis (AD), according …